Supinoxin™ Oral Administration Produces Clinically Meaningful Tumor Inhibition

In a poster presentation entitled “The Anti-Cancer Effects of Supinoxin (RX-5902) in Renal Cell Cancer,” Rexahn scientists detailed the results of several preclinical studies showing the antiproliferative effects of Supinoxin in various human renal cancer cell lines and xenograft renal cancer models.01/13/2016
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news